- Home
- PSF vs ZNTL Comparison
PSF vs ZNTL Comparison
Compare PSF & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- ZNTL
- Stock Information
- Founded
- PSF 2010
- ZNTL 2014
- Country
- PSF United States
- ZNTL United States
- Employees
- PSF N/A
- ZNTL N/A
- Industry
- PSF Investment Managers
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- PSF Finance
- ZNTL Health Care
- Exchange
- PSF Nasdaq
- ZNTL Nasdaq
- Market Cap
- PSF 246.0M
- ZNTL 273.1M
- IPO Year
- PSF N/A
- ZNTL 2020
- Fundamental
- Price
- PSF $20.15
- ZNTL $3.47
- Analyst Decision
- PSF
- ZNTL Buy
- Analyst Count
- PSF 0
- ZNTL 8
- Target Price
- PSF N/A
- ZNTL $10.50
- AVG Volume (30 Days)
- PSF 25.0K
- ZNTL 1.6M
- Earning Date
- PSF 01-01-0001
- ZNTL 11-12-2024
- Dividend Yield
- PSF 7.69%
- ZNTL N/A
- EPS Growth
- PSF N/A
- ZNTL N/A
- EPS
- PSF N/A
- ZNTL N/A
- Revenue
- PSF N/A
- ZNTL $40,560,000.00
- Revenue This Year
- PSF N/A
- ZNTL N/A
- Revenue Next Year
- PSF N/A
- ZNTL N/A
- P/E Ratio
- PSF N/A
- ZNTL N/A
- Revenue Growth
- PSF N/A
- ZNTL N/A
- 52 Week Low
- PSF $16.00
- ZNTL $2.66
- 52 Week High
- PSF $20.19
- ZNTL $18.07
- Technical
- Relative Strength Index (RSI)
- PSF 34.31
- ZNTL 49.60
- Support Level
- PSF $20.40
- ZNTL $3.65
- Resistance Level
- PSF $21.10
- ZNTL $4.44
- Average True Range (ATR)
- PSF 0.20
- ZNTL 0.42
- MACD
- PSF -0.04
- ZNTL 0.04
- Stochastic Oscillator
- PSF 10.75
- ZNTL 45.51
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.